Abstract 4399
Background
Data on the efficacy and safety of all targeted therapies for metastatic renal cell carcinoma (mRCC) including sunitinib are collected in the Czech RENIS patient registry. RENIS thus provides a uniquely large sample of long-term effectiveness and prognostic data of sunitinib according to adverse/risk factors measured by the Memorial Sloan Kettering Cancer Center (MSKCC) score. The aim of this study was to analyze the long-term overall (OS) and progression-free survival (PFS) of sunitinib, when used as 1st line treatment, based on MSKCC risk group scores including MSKCC scores for two intermediate subgroups.
Methods
Data from mRCC patients treated using sunitinib in the 1st line were collected in RENIS between 06/2007 and 02/2018. OS/PFS were then stratified based on MSKCC scores: a) favorable risk (0 adverse factors (AF)), b) intermediate risk (pooled 1–2 AFs), and c) poor risk (3+ AFs). The OS/PFS of the intermediate risk group was further stratified into two subgroups: i) 1 AF and ii) 2 AFs. All OS/PFS data were analyzed using Kaplan-Meier estimates. Differences in OS/PFS between risk groups were assessed using median survival, 95% confidence intervals (CI), and the log-rank test. Then we assessed the OS/PFS for 1-, 3-, and 5-year survival.
Results
Over the 11-year follow-up, 2390 patients were treated using sunitinib with 806, 1450, and 134 patients in the favorable, intermediate, and poor MSKCC risk groups. The more favorable MSKCC risk group was accompanied by an improved OS and PFS (p < 0.001). Regarding the MSKCC for the two intermediate sub-groups, 1 AF was associated with improved survival compared to 2 AFs (p < 0.001) (Table).Table:
957P OS and PFS results for sunitinib treatment based on MSKCC risk groups
MSKCC favorable | MSKCC intermediate | MSKCC poor | MSKCC intermediate | All patients | ||
---|---|---|---|---|---|---|
1 AF | 2 AFs | |||||
Overall survival | ||||||
Median survival (95% CI) | 44.7months (40.9-50.5) | 24.1months (21.9-26.0) | 9.5months (7.2-14.1) | 28.2months (25.9-30.7) | 16.2months (14.5-20.2) | 28.5months (26.3-30.5) |
1-year survival (95% CI) | 85.0% (82.4-87.6) | 69.1% (66.6-71.7) | 44.3% (35.0-53.7) | 74.3% (71.4-77.2) | 58.0% (53.1-62.9) | 73.3% (71.4-75.2) |
3-year survival (95 %CI) | 57.3% (53.4-61.3) | 37.1% (34.1-40.1) | 9.6% (3.1-16.2) | 42.0% (38.3-45.7) | 26.3% (21.4-31.2) | 42.9% (40.5-45.2) |
5-year survival (95% CI) | 35.6% (31.2-40.1) | 23.4% (20.4-26.4) | 3.2% (0.0-8.8) | 26.5% (22.7-30.3) | 16.5% (11.8-21.2) | 26.8% (24.3-29.2) |
n | 806 | 1450 | 134 | 969 | 481 | 2390 |
Log-rank p-value | < 0.001 | < 0.001 | - | |||
Progression-free survival | ||||||
Median survival (95% CI) | 17.0months (15.4-18.8) | 9.0months (8.3-9.5) | 4.5months (3.9-6.1) | 10.1months (9.4-11.4) | 6.2months (5.5-7.5) | 10.6months (9.9-11.5) |
1-year survival (95% CI) | 61.8% (58.3-65.3) | 40.7% (38.0-43.4) | 20.8% (13.1-28.5) | 45.1% (41.8-48.4) | 31.6% (27.1-36.1) | 46.9% (44.7-49.0) |
3-year survival (95 %CI) | 25.1% (21.7-28.5) | 13.0% (11.0-15.1) | 1.8% (0.0-5.1) | 15.9% (13.2-18.6) | 7.0% (4.2-9.7) | 16.6% (14.9-18.4) |
5-year survival (95% CI) | 10.4% (7.7-13.2) | 8.0% (6.2-9.8) | 1.8% (0.0-5.1) | 9.7 (7.3-12.0) | 4.5% (2.1-6.9) | 8.4% (7.0-9.9) |
n | 806 | 1450 | 134 | 969 | 481 | 2390 |
Log-rank p-value | < 0.001 | < 0.001 | - |
Conclusions
Better MSKCC risk scores were associated with significantly longer OS and PFS. To our knowledge, this is the largest published sunitinib mRCC cohort described relative to MSKCC risk groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Finek: Honoraria (self): Amgen; Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Bayer; Honoraria (self): Teva; Honoraria (self): MSD; Honoraria (self): Merck; Honoraria (self): Sanofi; Honoraria (self): Pierre Fabre. A. Poprach: Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Bayer. B. Melichar: Honoraria (self): BMS; Honoraria (self): Merck; Honoraria (self): MSD; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Astellas Pharma; Honoraria (self): Pfizer; Honoraria (self): Bayer. J. Kopecky: Honoraria (self): BMS; Honoraria (self): Novartis; Honoraria (self): Pfizer. M. Zemanova: Advisory / Consultancy: Novartis; Honoraria (self): Eli Lilly; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Boehringer Ingelheim. T. Buchler: Honoraria (self): Amgen; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: Janssen. K. Kopeckova: Honoraria (self): Novartis; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Pfizer. T. Mlcoch: Full / Part-time employment: Value Outcomes. T. Dolezal: Full / Part-time employment: Value Outcomes. All other authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract